Apogee Therapeutics, Inc. (APGE) Stock Analysis
Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $82.93: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Negative price momentum.
Apogee Therapeutics is a clinical-stage biotech developing extended half-life biologics for inflammatory and immunology conditions including atopic dermatitis, asthma, EoE, and COPD. It has no approved products and is pre-revenue, with four validated antibody programs in... Read more
Sell if holding. Engine safety override at $82.93: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductzumilokibart, APG279, APG273, APG990, APG333 and APG80810-K Item 1A: 'We are substantially dependent on the success of our product candidates, zumilokibart, APG279, APG273, APG990, APG333 and APG808'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $82.93: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $78.26. Score 5.1/10, moderate confidence.
Take-profit target: $105.18 (+27.0% upside). Prior stop was $78.26. Stop-loss: $78.26.
Concentration risk — Product: zumilokibart, APG279, APG273, APG990, APG333 and APG808; Quality below floor (1.4 < 4.0).
Apogee Therapeutics, Inc. trades at a P/E of N/A (forward -15.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts cover APGE with a consensus score of 4.3/5. Average price target: $117.
What does Apogee Therapeutics, Inc. do?Apogee Therapeutics is a clinical-stage biotech developing extended half-life biologics for inflammatory and immunology...
Apogee Therapeutics is a clinical-stage biotech developing extended half-life biologics for inflammatory and immunology conditions including atopic dermatitis, asthma, EoE, and COPD. It has no approved products and is pre-revenue, with four validated antibody programs in clinical trials. Accumulated deficit of $561.8M as of December 31, 2025.